Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

2(22.2%)

Early Phase 1

1(11.1%)

9Total

Phase 1(6)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07288138Phase 2Recruiting

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Role: lead

NCT07505303Phase 2Not Yet Recruiting

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Role: lead

NCT07334080Phase 1Recruiting

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Role: lead

NCT06988553Phase 1Completed

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

Role: lead

NCT05012423Phase 1Completed

FTIH Study of ECC0509 in Healthy Volunteers

Role: lead

NCT06293742Phase 1Completed

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

Role: lead

NCT06268145Phase 1Completed

ECC5004 RBA FE Study in Healthy Participants

Role: lead

NCT05654831Phase 1Completed

FTIH of ECC5004 in Healthy and Diabetic Participants

Role: lead

NCT05552274Early Phase 1Completed

FTIH of ECC4703 in Healthy Volunteers

Role: lead

All 9 trials loaded